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Abstract  We report the controlled release of the antibiotic tetracycline (Tet) from triple-
layered electrospun matrices consisting of zein or a zein/PCL blend, where the drug was 
loaded in the central layer with the outer two layers acting as diffusion barriers. These fibrous 
matrices successfully encapsulated Tet and efficiently inhibited the growth of a clinical 
isolate, the meticillin-resistant S. aureus strain MRSA252, as demonstrated in a modified 
Kirby-Bauer disc assay over five days. Whilst untreated zein fibres are unstable in an 
aqueous environment, rapidly shrinking due to plasticization and film formation, blending 
zein with PCL stabilized the electrospun matrices and prevented them from shrinking. These 
triple layer formulations displayed sustained antibiotic release and provide a proof of concept 
for zein-based polymeric matrices as wound dressings to treat or prevent bacterial infection. 
This is the first demonstration of the controlled release of a clinically-used antibiotic from 
electrospun zein-based matrices. 
 
 
 
 
 
Keywords  Antibiotic; Drug delivery; Electrospinning; Raman microscopy; Sustained 
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Introduction 
 
Electrospinning is a widely utilized technique for generating nano- and microfibres from a 
wide range of materials, including polysaccharides, proteins and synthetic polymers, alone or 
in blends [1,2]. A variety of fibre and matrix architectures can be achieved depending on how 
the fibres are spun and collected. For example, coaxial electrospinning [2,3] can generate 
fibres with a core and sheath feed consisting of the same or different polymers, often with a 
drug encapsulated in the centre of the fibres [4]. Modifications in the collection and 
processing of fibres can result in aligned fibres, tubes and matrices with macropores in 
addition to the randomly aligned fibres achieved with a stationary collector plate. The 
procedure is versatile, economical, simple to perform and allows the generation of 
electrospun structures with a number of desirable properties leading to many potential 
applications, e.g. packaging, filtration, drug releasing matrices, tissue engineering scaffolds 
and wound dressings [5-9]. From the perspective of translational medicine, the main 
advantage of electrospun matrices is that biocompatible nanofibres can mimic the structure 
and morphology of the extracellular matrix (ECM), resulting in a three-dimensional scaffold 
that replicates the cell-matrix interactions experienced by cells in vivo. By incorporating 
drugs or growth factors in electrospun matrices, bioactive implants have been developed for a 
range of translational applications in different tissues and disease states [9-12]. One such 
approach is the encapsulation of antibiotics in electrospun fibres [13,14] to treat infection, 
e.g. in burns patients or those with non-healing ulcers, or to prevent infection following 
invasive surgical procedures such as joint replacement [15]. This localized delivery from 
drug-loaded fibres aims to ensure that the affected tissue receives an efficacious dose of 
antibiotic while the patient avoids the off-target effects that often accompany a systemically-
delivered drug. 
For such long-term, sustained drug delivery applications, the majority of electrospun 
matrices described to date consist of a drug or drugs dissolved in a polymer solution, which is 
then processed to form a blended drug/polymer mat. Sustained drug release necessitates the 
use of hydrophobic polymers, preventing immediate hydration of the matrix, solubilisation of 
the drug and diffusion from the fibres. Drug release is controlled by diffusion and the long-
term surface and bulk erosion of the matrix, with one erosion mechanism usually dominating. 
Thus, as the polymer degrades, the drug is released. However, as electrospun matrices are 
comparable to the ECM and have a very high surface area to volume ratio, there is often a 
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significant burst release of drug that is on or near the surface of the fibres followed by a 
sustained release of the remainder of drug, encapsulated deeper within the polymer. To 
minimize burst release, drugs can be restricted to the fibre core by coaxial electrospinning, or 
rate-controlling layers can be incorporated to act as a physicochemical barrier to drug 
diffusion. 
There is a broad interest in developing electrospun matrices from natural products and 
these, to date, include a range of polysaccharides (e.g. alginate, chitosan, and cellulose) [16] 
and proteins (e.g. collagen, gelatin, laminin, silk fibroin) [10] from a variety of different 
plant, algal and animal species. However, the majority of these biopolymers are hydrophilic 
and this property makes them unsuitable for controlled drug release applications due to rapid 
hydration and drug release. Recently, there has been a renewed interest in the use of zein, the 
main prolamin storage protein in maize, due to its renewable source, biodegradability, 
biocompatibility and resistance to microbial degradation [1,17,18]. Zein is also hydrophobic, 
containing a significant proportion of non-polar amino acids, offering the possibility of 
sustained release of drugs encapsulated within electrospun zein matrices. Zein has been 
evaluated for its potential use in applications, including packaging, tissue engineering and 
drug delivery, either alone or in blends with other materials. For example, films have been 
employed to demonstrate the biocompatibility of zein with several cell types [5,17,18], and 
zein-based 3D bulk scaffolds have been postulated as potential scaffolds for bone tissue 
engineering [7,19-22]. Electrospun zein matrices [15,23] have been reported to be suitable 
tissue engineering, particularly for skin wound healing applications either alone [16,24] or 
blended with collagen [25]. 
For drug delivery applications, zein-based microparticles have been developed for the 
controlled release of antiparasitic [26], antibacterial [27,28], and anti-inflammatory [29] 
drugs. Electrospun zein-containing matrices have also been developed for controlled delivery 
of NSAIDs [30,31], antioxidants [32,33] and the antibiotic berberine [25], while 
zein/chitosan nanofibres have been shown to be biocidal due to chitosan’s known 
antibacterial properties [34]. However, despite good drug loading and demonstrable 
controlled release from electrospun zein-based matrices, the time taken for 100% release 
remains relatively short. For example, the total release of various NSAIDs reported in the 
literature ranges from 8-12 hours, despite modifications to the electrospinning process aimed 
to improve the release profile [30,35,36]. 
In this study, our aim was to develop an electrospun zein-based matrix for the 
encapsulation and sustained release of a model antibiotic, tetracycline (Tet). This would find 
	   5 
medical applications as a biocompatible wound dressing, but would, ultimately, also be 
potentially applicable in vivo as an implant for the prevention of infection following invasive 
procedures or as a tissue engineering scaffold. We report the development of single-layer 
matrices and, in an effort to reduce burst release, triple-layer (3L) formulations. In the latter, 
the outer layers are drug-free and designed to act as a diffusion barrier. To our knowledge, 
these are the first triple-layer, zein-based matrices and demonstrate the first reported extended 
release of a clinically-used antibiotic from such electrospun zein-based formulations. 
 
 
Materials and Methods 
 
Materials 
 
Zein was purchased from Acros Organics. Müller-Hinton (MH) agar and Tryptone Soya 
Broth (TSB) were purchased from Oxoid. The bacterial strain used in this study was 
Staphylococcus aureus MRSA252 [37], kindly provided by Dr Albert Bolhuis, University of 
Bath. Poly-ε-caprolactone (PCL; Mn 70,000 to 90,000), tetracycline (Tet) HCl and all other 
chemicals and solvents were purchased from Sigma Aldrich. Gene frames (1x1 cm) and 
plastic coverslips were purchased from Fisher Scientific. 
 
Polymer solutions 
 
Zein solution was prepared at 30% (w/v) in a 1:1 (v/v) mixture of 2,2,2-trifluoroethanol 
(TFE):dichloromethane (DCM). Tet HCl was dissolved in TFE at 5% (w/w) with respect to 
the protein prior to mixing with DCM. For blended matrices of zein and PCL, zein was 
dissolved at 20% or 25% (w/v) and PCL at 10% or 5% (w/v) in 1:1 (v/v) TFE:DCM, 
resulting in solutions with a total polymer concentration of 30% (w/v). Tet HCl was again 
incorporated at 5% relative to the polymer mass. 
 
Electrospinning 
 
The polymer solution was loaded into a glass syringe and electrospun at 18 kV with a flow 
rate of 0.75 mL/h and the distance between the tip of the needle and the collector set at 13 
cm. Flow rate was controlled by a syringe infusion pump (Cole Parmer). The electrospun 
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matrices were collected on two parallel metal electrodes covered with aluminium foil. To 
fabricate layered mats, each polymer solution was electrospun using a fixed volume for each 
layer (1 mL for the outer layers and 0.5 mL for the inner layer) in a layer-by-layer manner. 
Five matrices were produced: single-layer zein, single-layer zein/PCL (25:5), single-layer 
zein/PCL (20:10), triple-layered (3L) zein and 3L zein/PCL (20:10). In single-layer matrices, 
Tet HCl was electrospun at 5% (w/w). In the 3L matrices, Tet HCl was incorporated only in 
the middle layer at 5% (w/w), with the two outer layers being drug-free. Three replicates of 
each formulation were fabricated. 
 
Assessment of matrix stability 
 
To investigate the ability of the polymeric fibrous matrices to maintain their morphology 
when exposed to an aqueous environment, three different single-layer mats were examined:  
zein, zein/PCL (25:5), and zein/PCL (20:10), all containing Tet HCl. Matrices were punched 
into 9 mm discs, imaged with a digital camera and then incubated in phosphate-buffered 
saline (PBS; pH 7.4) at 37 °C for 7 days. Discs were then removed from the buffer, imaged 
while still wet and then allowed to dry for 3 days at 20 °C before being imaged again. The 
maximum and minimum diameters of each disc were determined using ImageJ (NIH, 
Bethesda, MD; http://rsb.info.nih.gov/ij/) and the mean diameters compared to that of the 
discs prior to wetting with PBS buffer. Triplicate samples were examined for each 
formulation and the experiment was performed three times with independently electrospun 
mats. 
 
Morphology of electrospun matrices 
 
The surface morphology of electrospun matrices was observed by scanning electron 
microscopy (SEM; JEOL JSM-6480LV) before and after exposure to PBS at 37 °C. The 
matrices were cut into small cm2 sized pieces, sputter-coated with gold (Edwards Sputter 
Coater 5150B) and then analysed by SEM with an accelerating voltage from 10 kV. The 
mean fibre diameter was determined by randomly selecting 60 fibres from three separate 
images and measuring their diameters using ImageJ software. 
 
Raman microscopy 
 
	   7 
Raman spectra were obtained using a Renishaw inVia Imaging Microscope with a near-
infrared diode laser (785 nm) as the excitation source, using approximately 32 mW of power 
at the sample surface and a 1,200 lines/mm grating. Streamline maps of the sample were 
obtained at 20 µm line focus with an exposure time of 30 s/line. Irradiation was uniform 
across the window 900-1,900 cm-1. 
 
Tetracycline hydrochloride encapsulation efficiency 
 
To determine the encapsulation efficiency of the electrospun matrices, the mats were cut into 
small discs (~6 mm diameter), weighed and then dissolved in methanol:DCM (1:1 v/v, 10 
mL). The UV absorbance was measured at λ = 360 nm (subtracting for zein absorbance at 
this wavelength) and the amount of Tet HCl in the fibres was then calculated using a Tet HCl 
calibration curve and subsequently compared to the theoretical value (5%). Triplicate 
samples were examined for each formulation and the experiment was performed three times 
with independently electrospun mats. 
 
In vitro drug release studies 
 
The electrospun matrices were cut into 1.2 cm squares and, to minimise the effect of drug 
release from the edges, the samples were adhered to a plastic coverslip using a gene frame to 
give an available release surface of 1 cm2. Each sample was placed in PBS buffer (5 mL; pH 
= 7.4) in a plastic vial and incubated at 37 °C. At specific time intervals, the buffer was 
replaced and the withdrawn sample assayed by UV spectroscopy at λ = 360 nm to determine 
Tet release against a standard curve. The cumulative percentage release at each time point 
was determined by comparing the actual mass release with the mass of Tet in each sample, 
calculated using the encapsulation efficiency data for each individual mat. Triplicate samples 
were examined for each formulation and the experiment was performed three times with 
independently electrospun mats. 
 
Antibacterial efficacy of Tet HCl-loaded nanofibrous layered matrices 
 
Tet HCl-sensitive bacteria, S. aureus MRSA252 [37], were used to investigate the efficacy of 
Tet released from the zein-based electrospun matrices with a modified Kirby-Bauer test 
[13,14,38]. S. aureus suspension was incubated for 16 h in TSB and subsequently diluted 
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with sterile TSB containing 0.5% glucose (w/v) and 3% NaCl (w/v) to obtain an absorbance 
value of ~0.035 at 600 nm. Then, 100 µL of the diluted bacteria solution was streaked onto 
the surface of a MH agar plate (prepared previously according to the manufacturer’s 
instructions) followed by placing the electrospun matrices on the plates. The matrices were 
cut into discs, each containing 270 µg Tet HCl, with a filter paper disc loaded with 270 µg 
Tet HCl (applied as a methanolic solution) as a positive control. Three replicates of one 
formulation and one Tet HCl-loaded filter paper disc were placed on each MH agar plate and 
incubated at 37 °C for 24 h. After this time, the inhibition zones around the discs were 
measured and the discs were then transferred to new MH agar plates pre-streaked with fresh 
bacteria. Following incubation for a further 24 h at 37 °C, the new inhibition zones were 
determined and this procedure was repeated for a total of five days. The average inhibition 
zones, determined by measuring the diameter of the zones of inhibition and subtracting the 
diameter of the matrix disc, were expressed as the mean ± standard deviation (n=3). Student’s 
t-tests were performed using Microsoft Excel to determine any statistically significant 
differences between the formulations. P<0.05 was considered to be significant. 
 
 
Results and Discussion 
 
Effect of aqueous environment on electrospun zein and zein/PCL matrices 
 
Initial attempts at electrospinning zein using aqueous alcohol, neat TFE or acetic acid 
produced inconsistent results with either a complete lack of fibres or significant beading (data 
not shown). However, electrospinning zein at 30% (w/v) in a 1:1 (v/v) mixture resulted in the 
successful and reproducible production of matrices with continuous, non-beaded fibres. 
When discs of electrospun zein matrices were placed in aqueous buffer at 37 °C for 7 days, 
we observed a drastic reduction in their size from an initial diameter of 9 mm to 
approximately 3 mm (Fig. 1a), with this shrinkage effect visibly noticeable in <30 min. Even 
when discs were placed in contact with agar plates, this deformation was marked (data not 
shown). It is well established that electrospun protein-based fibres lose their integrity in an 
aqueous environment [39,40]. Hydrophilic proteins such as gelatin and collagen absorb 
water, swell and dissolve. Zein fibres are also unstable in water, but due to their hydrophobic 
nature, this instability occurs by a different mechanism. Water has a plasticisation effect on 
zein [41], with exposure causing a fibrous electrospun matrix to become film-like [35,41-44]. 
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For application of pure, unblended zein fibres as a wound dressing, this shrinkage would be 
detrimental, as complete coverage of the damaged tissue needs to be maintained. We 
therefore designed means of overcoming this phenomenon. Numerous methods have been 
reported in the literature to stabilize protein matrices of various morphologies from particles 
to sponges to fibres. These methods predominantly rely on chemical crosslinking using a 
variety of species including genipin [45], glutaraldehyde [46] and carbodiimides [47], 
although, depending on the protein, other techniques such as autoclaving may be effective 
[48]. Zein has been successfully crosslinked using hexamethylene diisocyanate [49], while 
Jiang and co-workers have reported successful stabilization using citric acid either with 
NaOH catalysis [35] or by heating at 150 °C [43]. However, for drug encapsulation, none of 
these crosslinking and stabilization methods is suitable due to the possibility of chemical or 
physical alteration/degradation of the drug molecule, potentially rendering it inactive or even 
toxic.  
An alternative strategy for the stabilization of protein-containing matrices is to blend 
the protein with a water-stable polymer, and this is established in the literature, in particular 
for tissue engineering scaffolds [39,40,50]. Therefore, to prevent the drastic shrinkage 
observed when electrospun zein discs were exposed to water, we investigated blends of zein 
and PCL, an FDA-approved biocompatible and biodegradable polymer that has been used in 
areas such as controlled drug delivery and tissue engineering [51]. When solutions of zein 
and PCL were electrospun at ratios of 25:5 and 20:10 (w/v), using the same conditions as 
those employed for pure zein, fibrous matrices were successfully prepared. Discs of these 
matrices were subsequently exposed to PBS for 7 days at 37 °C and no shrinkage was 
observed (Fig. 1a, b), showing that blending zein with PCL stabilized the protein as intended. 
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Fig. 1 a Representative images of electrospun single layer zein and zein/PCL matrices prior 
to exposure to aqueous buffer (initial diameter = 9 mm) and following immersion in PBS for 
7 days at 37 °C. Images of immersed discs were obtained following 3 days drying at 20 °C. 
Scale bar = 5 mm. b Mean disc diameter from all formulations prior to buffer exposure in 
comparison to disc diameters measured immediately after retrieval from buffer (wet) and 
following 3 days drying at 20 °C (dried). The error bars represent the standard deviation of 
the mean (n=3 in triplicate) 
 
 
Matrix Morphology 
 
The morphology of the electrospun matrices was examined by scanning electron microscopy 
before and after exposure to PBS (Fig. 2). SEM revealed the successful formation of smooth, 
continuous fibres with no evidence of beading or electrospraying. The diameters of as-spun 
zein fibres, both single-layer and 3L (Fig. 2a, c) were visually considerably smaller than 
those of the zein/PCL blends (Fig. 2e, g, i) and, as expected, following incubation in aqueous 
buffer, the zein matrices lost their fibrous structure and formed films (Fig. 2b, d), confirming 
the observations of the shrinkage experiments shown in Figure 1. The presence of PCL 
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within the blended electrospun fibres had a dramatic effect on matrix stability, with no 
apparent differences between the zein/PCL fibres before and after immersion in buffer (Fig. 
1f, h, j). 
 
 
Fig. 2 Representative SEM images of (a, b) electrospun zein; (c, d) zein 3L; (e, f) zein/PCL 
(25:5), (g, h) zein/PCL (20:10) and (i, j) zein/PCL (20:10) 3L matrices before (a, c, e, g, i) 
and after (b, d, f, h, j) immersion in PBS at 37 °C. Matrices were immersed in buffer for 7 (b, 
f, h), 14 (j) or 32 days (d). Scale bars = 5 µm 
 
Average fibre diameters were determined from the SEM images and are shown in 
Table 1. The average diameter of fibres in a single-layer of zein was 0.67±0.19 µm in 
comparison to 0.99±0.36 µm for the zein 3L matrix. This increased fibre diameter in the 3L 
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formulation may be explained by two factors. Firstly, the SEM images were of the top 
surface of the electrospun matrices meaning that, for the single-layer matrix, the observed 
fibres contained Tet HCl while, for the 3L matrix, the visible fibres were drug-free. As a 
charged species, Tet HCl increases the conductivity of the electrospinning solution with a 
resultant decrease in fibre diameter, potentially explaining the smaller diameter of single-
layer zein fibres. Alternatively, it has been previously shown that as fibres are deposited 
during the electrospinning process, the charge build-up on the matrix surface decreases fibre 
stretching, thus increasing diameter [52]. This phenomenon could explain the greater 
diameter of the observed zein 3L fibres. An investigation of the dimensions of internal fibres 
could have helped determine the relationship between spinning conditions and fibre diameter. 
Unfortunately, attempts to freeze-fracture 3L matrices proved unsuccessful. 
 Electrospun zein/PCL fibres were thicker than zein fibres and had a greater 
variability, with diameters of 1.96±0.69 µm for single-layer zein/PCL (25:5), 1.69±0.60 µm 
for single-layer zein/PCL (20:10) and 1.51±0.65 µm for zein/PCL (20:10) 3L (Table 1). This 
increase in diameter may be due to changes in the conductivity and viscosity of the 
electrospinning solution on addition of PCL. However, amongst the blended matrices 
themselves, there were no apparent trends in fibre thickness. If a relationship exists between 
relative PCL concentration or the effect of layering on fibre diameter, it may be masked by 
the variation that was observed in fibre thicknesses on individual matrices. When the effect of 
immersion in buffer on fibre diameter was examined, there was again no apparent difference 
between the individual formulations and no changes compared to the as-spun diameters, 
demonstrating the stability of these blends in an aqueous environment (Table 1). 
 
 Mean fibre diameter (µm) 
Matrix Before After 
Zein 0.67 ± 0.19 Filma 
Zein 3L 0.99 ± 0.36 Filmc 
Zein/PCL (25:5) 1.96 ± 0.69 1.34 ± 0.45a 
Zein/PCL (20:10) 1.69 ± 0.60 1.92 ± 0.43a 
Zein/PCL (20:10) 3L 1.51 ± 0.65 1.30 ± 0.59b 
 
Table 1. Diameters of electrospun zein and zein/PCL fibres before and after immersion in 
PBS at 37 °C. Diameters of fibres on the top surface of each matrix were determined from 
SEM images and are expressed as the mean ± standard deviation of 60 fibres per formulation. 
Matrices were exposed to PBS for a7, b14 or c32 days 
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Determination of drug and polymer distribution by Raman microscopy 
 
For eventual applications in wound dressings, it is important that the components of the 
electrospun matrices, especially the drug, are homogeneously distributed to ensure consistent 
release. To assess this, Raman spectra were obtained individually for zein, PCL and Tet and, 
using this information, Raman microscopy was used to image the individual components of 
electrospun zein/PCL (20:10) with 5% (w/w) Tet. Uniform distribution of all three species 
was observed (Fig. 3).  
 
Fig. 3 Raman microscopy of an electrospun zein/PCL (20:10) blend with 5% (w/w) Tet. (a) 
White light; (b) zein; (c) PCL; (d) Tet; (e) zein + Tet overlay and (f) zein + PCL +Tet 
overlay. Scale bar = 1 mm. 
 
 
In vitro release of tetracycline zein and zein/PCL matrices 
 
Prior to release studies, the encapsulation efficiency of each matrix formulation was 
determined. Within experimental error, encapsulation was quantitative for all but the 
zein/PCL (20:10) 3L samples, which had an encapsulation efficiency of 71±11%. The release 
a b c 
d e f 
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profiles of Tet from the electrospun zein and zein/PCL matrices into PBS at 37 °C are shown 
in Figure 4. The single-layer zein matrix exhibited a burst release of ~65% of the drug within 
the first 3 h (Fig. 4a), followed by a sustained drug release up to ~83% at 10 days, after 
which the release plateaued (Fig. 4b). Zein 3L proved to be a more controlled formulation 
than the single-layer equivalent, with an initial burst of ~45% of the Tet in the first 3 h (Fig. 
4a) followed by a sustained release which continued until the experiment was terminated (27 
days), after which  ~70% of the encapsulated drug had been released (Fig. 4b). An extension 
of the sustained release capacity of zein would be expected by the addition of drug-free, rate-
controlling layers that sandwich the central, Tet-containing matrix. However, this effect is 
likely to have been exacerbated by the transition of the fibrous zein matrices to film-like 
structures (Fig. 2b, d), with the outer layers of the 3L structure presenting more of a physical 
barrier than if the structure had remained fibrous. The shift from fibre to film occurred 
rapidly (<30 min), so this effect dominated the release kinetics, resulting in lengthy, sustained 
Tet release from the zein 3L matrix. 
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Fig. 4 Release profiles of Tet from electrospun zein and zein/PCL matrices into PBS at 37 
°C. a First 24 hours and b longer term release. The error bars represent the standard 
deviation of the mean (n=3 in triplicate) 
 
 When the single-layer zein/PCL matrices (25:5 and 20:10) were examined, they 
exhibited near-identical Tet release profiles, with a burst of ~70% of the encapsulated drug 
within the first 3 h (Fig. 4a), followed by a more sustained release of ~20% of the drug over 
the next 1-2 days before reaching a plateau (Fig. 4b). In comparison with the single-layer zein 
matrix, these formulations exhibited a greater burst release and less sustained release. This is 
possibly due to the chemical nature of the two components of the blended formulations. 
Although predominantly hydrophobic, zein, as a protein, is amphiphilic, and it would be 
expected that the encapsulated Tet would interact with the more polar amino acid residues. 
PCL, however, is hydrophobic and does not possess amphiphilic character, hence blending it 
with zein is likely to reduce the affinity of the Tet for the matrix and accelerate its release.  
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Due to their high similarity, only the zein/PCL (20:10) 3L formulation was chosen as 
it performed marginally better than 25:5 in stability testing and would offer greater 
mechanical properties for any eventual medical applications. The sharp burst release seen in 
the other matrices was absent from the zein/PCL (20:10) 3L formulation, with a gradual 
release of ~50% of the encapsulated Tet over the first 24 h (Fig. 4a). This demonstrates that, 
in comparison to the single-layer equivalent, the Tet-free outer layers in zein/PCL (20:10) 3L 
successfully control the release of Tet, acting as a hydrophobic barrier to water ingress and 
subsequent drug diffusion from the inside of the matrix. This control of drug release 
continued after 24 h, with a sustained release of a further ~15% of the encapsulated Tet over 
the next 14 days (Fig. 4b). When compared with zein 3L, the zein/PCL (20:10) 3L matrix 
exhibited a less controlled, more variable release, possibly due to the Tet being able to diffuse 
more freely through the more open, albeit hydrophobic, structure of the PCL-stabilised, 
fibrous matrix rather than it being physically entrapped within a dense film within the zein 3L 
matrix. Nevertheless, both 3L formulations exhibited the desired improvement in sustained 
release when compared to the single-layer equivalents as a result of the added drug diffusion 
barriers. 
The Tet release profiles presented here are superior to those reported in the literature 
for zein-based electrospun scaffolds. While we have produced matrices capable of sustained 
drug release over a period >2 weeks, previously reported electrospun zein fibres have much 
shorter release windows. For example, crosslinked electrospun zein fibres released their 
encapsulated diclofenac within 10 h [35], while, using coaxial electrospinning techniques, 
ketoprofen [36] and ferulic acid [33] were encapsulated within zein fibres and subsequently 
released in 12 and 14 h, respectively. Blending zein and collagen has been shown to increase 
sustained delivery, with berberine largely plateauing by ~5 days [25]. Therefore, by using 
non-crosslinked electrospun zein as a single or 3L matrix, or by using a 3L zein/PCL (20:10) 
blend, longer-term delivery of therapeutic drugs is achievable. The timescales presented here 
are comparable with those of Tet released from zein/PLGA microparticles, which had been 
compressed into monolithic matrices [28]. 
However, the blended matrices described here exhibited a greater burst release than 
pure zein and, subsequently, a less controlled delivery of the encapsulated Tet. While this is 
not the ideal scenario, sustained release was still achieved and the increase in stability 
conferred on the matrix by the inclusion of PCL is significant. For translational applications, 
such as wound dressings, shrinkage is not desirable, as it would result in exposure of the 
wound. Blending zein with PCL successfully prevented this phenomenon. 
	   17 
 
Antibacterial efficacy of zein and zein/PCL matrices 
 
The antibacterial activity of the Tet released from the zein-based electrospun matrices was 
assessed by bacteria inhibition experiments against the clinically-relevant meticillin-resistant 
S. aureus strain, MRSA252. Bacteria were challenged with discs of the electrospun matrices 
containing Tet (270 µg) and compared to a filter paper disc loaded with that same dose of Tet 
as a positive control. On a daily basis, the inhibition zone around each disc was measured and 
the discs transferred to a new agar plate. This process was continued for five days and the 
results are shown in Figure 5. All formulations exhibited a significant inhibition of S. aureus 
growth after 1 day, but all electrospun matrices had smaller zones of inhibition than the 
positive control, indicating a slower and more controlled release of Tet. This difference was 
statistically significant (P<0.05) for single-layer and 3L zein matrices and zein/PCL (20:10) 
3L, but not for single-layer zein/PCL (20:10), correlating with the release profiles of these 
matrices, where zein/PCL (20:10) exhibited the highest burst release of these four 
formulations. Electrospun zein with no encapsulated Tet was ineffective, with no inhibition 
of bacterial growth (not shown), as previously demonstrated by Torres-Giner et al [34,53]. 
We have previously shown that electrospun PCL is also ineffective in this assay [13], 
suggesting that the antibacterial effects of the matrices in this study were solely due to the 
release of encapsulated Tet.  
 
Fig. 5 Inhibition zones surrounding discs of Tet-containing electrospun zein and zein/PCL 
matrices in the S. aureus susceptibility test. The error bars represent the standard deviation 
of the mean (n=3 in triplicate; * P<0.05, **P<0.01, ***P<0.001) 
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After 2 days, the inhibition zone around the positive control was significantly 
reduced, while those around the electrospun matrices were of a similar diameter to the 1day 
results, indicating a degree of controlled Tet release. The zein/PCL (20:10) matrix exhibited 
the largest inhibition zone, significantly greater than zein, zein 3L and the positive control 
(P<0.01), likely due to this formulation having the greatest rate of Tet release (i.e. burst) over 
a 48 h period (Fig. 4b). After 3 days, the positive control was spent and there was no 
evidence that the Tet-soaked filter paper possessed any additional antibacterial activity. 
However, all of the electrospun zein-based matrices continued to release a significant amount 
of Tet as evidenced by the substantial inhibition zones where the MRSA252 bacteria were 
unable to grow (Fig. 5). By day 4, all matrices were still able to kill the bacteria, although the 
inhibition zones surrounding the zein/PCL blends smaller than those of zein and zein 3L, 
with zein/PCL (20:10) being significantly less effective than the zein-only matrices (P<0.01 
and P<0.05, respectively). This difference in efficacy was even greater at day 5, with zein 
and zein 3L maintaining similar zones of inhibition to those on previous days, while the 
zones of inhibition around the zein/PCL blends were further reduced. These differences 
correlate with the release profiles, with zein and zein 3L exhibiting higher release rates for a 
longer time period than the zein/PCL blends, where the Tet release rate dropped after the 
initial 2 days. However, despite the efficacy of the blended matrices being lower, all four 
formulations produced promising antibacterial activity over the whole 5 day period, 
demonstrating a sustained release of a biologically active amount of Tet, capable of killing 
and preventing the growth of a clinically-relevant strain of S. aureus. 
 
We have demonstrated that electrospun zein matrices are unstable in an aqueous 
environment, even on an agar plate, with matrix shrinkage and deformation due to 
plasticization and film formation. However, blending zein with PCL (20:10 or 25:5 w/w) 
stabilized the electrospun fibres and prevented the matrices from shrinking. Such zein and 
zein/PCL matrices released Tet in a controlled manner, with a more extended release from 3L 
matrices. The Tet released from these matrices prevented the growth of MRSA252 for at least 
five days, supporting our proposal that these electrospun mats could be used as wound 
dressings to treat or prevent bacterial infection. Thus, we report the first demonstrated 
controlled delivery of a clinically-used antibiotic from electrospun triple-layer zein-based 
matrices. Indeed, the Tet release profiles presented here are superior to those reported in the 
literature for zein-based electrospun scaffolds which we consider to be due to the outer, drug-
free layers acting as a diffusion barrier. We have designed and prepared a sustained release 
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formulation capable of killing S. aureus MRSA252, a multidrug-resistant clinical isolate that 
is a representative of an epidemic lineage endemic in UK hospitals. 
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